| scholarly article | Q13442814 |
| P50 | author | Kenji Hashimoto | Q70911404 |
| P2093 | author name string | Chun Yang | |
| Shigeyuki Chaki | |||
| Hiroyuki Koike | |||
| Jun-Ichi Yamaguchi | |||
| Youge Qu | |||
| Akiko Mizuno-Yasuhira | |||
| Hidetoh Toki | |||
| P2860 | cites work | R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects | Q28266846 |
| Ketamine's antidepressant action: beyond NMDA receptor inhibition | Q28278684 | ||
| R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine | Q28303539 | ||
| Antidepressant effects of ketamine in depressed patients | Q29617327 | ||
| A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 | ||
| NMDAR inhibition-independent antidepressant actions of ketamine metabolites. | Q30370600 | ||
| Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation | Q34460057 | ||
| Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test | Q36127598 | ||
| Stereoselective and regiospecific hydroxylation of ketamine and norketamine | Q36186055 | ||
| Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression | Q36233963 | ||
| Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories | Q37424333 | ||
| Drug interaction study between bupropion and ticlopidine in male CF-1 mice | Q39775832 | ||
| Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys | Q44135052 | ||
| Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling | Q44952028 | ||
| Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit | Q47306135 | ||
| Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine. | Q47338721 | ||
| Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression | Q47403269 | ||
| Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects. | Q47570724 | ||
| Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine | Q47572680 | ||
| Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model. | Q47683691 | ||
| (R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine. | Q47822871 | ||
| Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation. | Q47882199 | ||
| Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine | Q48251035 | ||
| Pharmacological interaction with the sigma1 (σ1)-receptor in the acute behavioral effects of antidepressants | Q48887628 | ||
| Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations. | Q51864897 | ||
| Effects of a ketamine metabolite on synaptic NMDAR function. | Q55060170 | ||
| In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice | Q87825044 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1900-1907 | |
| P577 | publication date | 2018-05-03 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice | |
| P478 | volume | 43 |
| Q92043421 | (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism |
| Q64111576 | Decoding the Mechanism of Action of Rapid-Acting Antidepressant Treatment Strategies: Does Gender Matter? |
| Q60047223 | Is the History Repeated? Can (2R,6R)-Hydroxynorketamine be Another Antidepressant? |
| Q95642618 | Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers |
| Q90631290 | Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives |
| Q89548916 | Ketamine: Leading us into the future for development of antidepressants |
| Q91173369 | Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites |
| Q89076158 | No Sex-Specific Differences in the Acute Antidepressant Actions of (R)-Ketamine in an Inflammation Model |
| Q92873306 | Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective |
| Q94954574 | Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine |
| Q89923969 | The Effects of General Anesthetics on Synaptic Transmission |
| Q104509545 | The stress susceptibility factor FKBP51 controls S-ketamine-evoked release of mBDNF in the prefrontal cortex of mice |
Search more.